Видео ютуба по тегу Allo-Sct

Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?
Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?
Impact of conditioning intensity of allo-SCT for AML with molecular residual disease
Impact of conditioning intensity of allo-SCT for AML with molecular residual disease
Allo-SCT in older patients with MDS: selection, donors, and timing
Allo-SCT in older patients with MDS: selection, donors, and timing
Optimizing the timing of alloSCT in MPN-AP/BP: the importance of disease control
Optimizing the timing of alloSCT in MPN-AP/BP: the importance of disease control
HL: AUTO VS ALLO SCT, WILLIAM HWANG
HL: AUTO VS ALLO SCT, WILLIAM HWANG
allo-SCT improves survival following venetoclax and azacitidine therapy in AML
allo-SCT improves survival following venetoclax and azacitidine therapy in AML
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
Brissot: Comparing Matched-Sibling Donors in allo-SCT
Brissot: Comparing Matched-Sibling Donors in allo-SCT
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
Investigating relapse after allo-SCT in AML
Investigating relapse after allo-SCT in AML
Prevention, detection and treatment of AML relapse after allo-SCT
Prevention, detection and treatment of AML relapse after allo-SCT
Dr. Babak Nejati : Concepts and Future Direction of Allo-SCT
Dr. Babak Nejati : Concepts and Future Direction of Allo-SCT
When should we consider allo-SCT for patients with MDS?
When should we consider allo-SCT for patients with MDS?
Allogeneic Stem Cell Transplants
Allogeneic Stem Cell Transplants
How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?
How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?
Осложнения аллогенной трансплантации стволовых клеток (алло-ТСК)
Осложнения аллогенной трансплантации стволовых клеток (алло-ТСК)
How donor age impacts outcomes in patients with AML undergoing alloSCT
How donor age impacts outcomes in patients with AML undergoing alloSCT
The clearance of driver mutations following alloSCT impacts myelofibrosis disease outcomes
The clearance of driver mutations following alloSCT impacts myelofibrosis disease outcomes
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
GO-FLAG: bridge therapy to allo-SCT in R/R AML
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Biomarkers for GvHD risk in allo-SCT
Biomarkers for GvHD risk in allo-SCT
Challenges of CAR-T bridging to allo-SCT
Challenges of CAR-T bridging to allo-SCT
FLT3 inhibitor maintenance after allo-SCT for AML
FLT3 inhibitor maintenance after allo-SCT for AML
Choosing between gene therapy and alloSCT for SCD
Choosing between gene therapy and alloSCT for SCD
Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?
Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?